Setipiprant

Setipiprant (ACT-129968) is an orally active and selective CRTH2 antagonist. Setipiprant interacts with hCRTH2 receptor with an IC50 value of 6 nM. Setipiprant inhibits prostanoid receptors hDP1 and hEP2 with IC50 values of 1290 and 2600 nM, respectively. Setipiprant can be used for the research of asthma and rhinitis[1].

Product Specifications

CAS Number

[866460-33-5]

Product Name Alternative

ACT-129968; KYTH-105

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

CRTH2 (GPR44) ; Prostaglandin Receptor

Type

Reference compound

Related Pathways

GPCR/G Protein; Immunology/Inflammation

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology; Endocrinology

Assay Protocol

https://www.medchemexpress.com/Setipiprant.html

Purity

98.23

Solubility

DMSO : ≥ 36 mg/mL

Smiles

O=C(O)CN1C2=C(CN(C(C3=C4C=CC=CC4=CC=C3)=O)CC2)C5=C1C=CC(F)=C5

Molecular Formula

C24H19FN2O3

Molecular Weight

402.42

Precautions

H302, H315, H319, H335

References & Citations

[1]Heinz Fretz, et al. Identification of 2 (2- (1-Naphthoyl) -8-fluoro-3,4-dihydro 1H pyrido[4,3 b]indol-5 (2H) yl) acetic Acid (Setipiprant/ACT 129968), a Potent, Selective, and Orally Bioavailable Chemoattractant Receptor-Homologous Molecule Expressed on Th2 Cells (CRTH2) Antagonis. 2013.